Development of systemic sclerosis in patients with autoimmune hepatitis

An emerging overlap syndrome

Roberto Assandri, Marta Monari, Alessandro Montanelli

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: We described two case reports of AIH/SSc overlap syndrome and reviewed literatures regarding this issue. Background: AIH is a chronic hepatitis of unknown aetiology characterized by continuing hepatocellular necrosis and inflammation. AIH overlap syndromes have been reported with other autoimmune diseases. Patients and methods: According to the classification criteria for SSc, we conducted a retrospective chart review of 35 cases with biopsy-proven AIH over the past 5 years at our institution. We reviewed the MEDLINE database using the appropriate key-words. Results: A chart review of 35 cases (M/F ratio 1:2, mean age 47.6±10.3 years) revealed nine patients (9/35, 25.7%) with CTD (four males and three females with a mean age of 45.1±8.4 years). All patients had ANA. Four patients were SSA/Ro positive UCTD (1/35, 2.85%), and six patients developed SLE (6/35, 17.1%). Only two female patients (2/35, 5.7%) with specific SSc AAb developed a systemic sclerosis. We described a patient with AIH who was diagnosed with diffuse systemic sclerosis-sine scleroderma with positive anti-centromere B and SSA/Ro52 KDa antibodies. We also reported a patient with AIH who was diagnosed limited SSc with contemporary presence of anti-centromere A and anti-RNA polymerase III antibody. Conclusion: We suggest that SSc may be considered to be one of the manifestations associated with AIH. Patients with AIH may have an increased risk to develop SSc and should be followed, especially when Raynaud phenomenon was found.

Original languageEnglish
Pages (from-to)211-219
Number of pages9
JournalGastroenterology and Hepatology from Bed to Bench
Volume9
Issue number3
Publication statusPublished - 2016

Fingerprint

Insemination, Artificial, Homologous
Autoimmune Hepatitis
Systemic Scleroderma
Centromere
RNA Polymerase III
Diffuse Scleroderma
Raynaud Disease
Antibodies
Chronic Hepatitis
MEDLINE
Autoimmune Diseases
Necrosis
Databases
Inflammation
Biopsy

Keywords

  • Autoimmune hepatitis
  • Autoimmune liver diseases
  • Systemic sclerosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Development of systemic sclerosis in patients with autoimmune hepatitis : An emerging overlap syndrome. / Assandri, Roberto; Monari, Marta; Montanelli, Alessandro.

In: Gastroenterology and Hepatology from Bed to Bench, Vol. 9, No. 3, 2016, p. 211-219.

Research output: Contribution to journalArticle

@article{3b769cf9874d4707890744e3cbb0bf33,
title = "Development of systemic sclerosis in patients with autoimmune hepatitis: An emerging overlap syndrome",
abstract = "Aim: We described two case reports of AIH/SSc overlap syndrome and reviewed literatures regarding this issue. Background: AIH is a chronic hepatitis of unknown aetiology characterized by continuing hepatocellular necrosis and inflammation. AIH overlap syndromes have been reported with other autoimmune diseases. Patients and methods: According to the classification criteria for SSc, we conducted a retrospective chart review of 35 cases with biopsy-proven AIH over the past 5 years at our institution. We reviewed the MEDLINE database using the appropriate key-words. Results: A chart review of 35 cases (M/F ratio 1:2, mean age 47.6±10.3 years) revealed nine patients (9/35, 25.7{\%}) with CTD (four males and three females with a mean age of 45.1±8.4 years). All patients had ANA. Four patients were SSA/Ro positive UCTD (1/35, 2.85{\%}), and six patients developed SLE (6/35, 17.1{\%}). Only two female patients (2/35, 5.7{\%}) with specific SSc AAb developed a systemic sclerosis. We described a patient with AIH who was diagnosed with diffuse systemic sclerosis-sine scleroderma with positive anti-centromere B and SSA/Ro52 KDa antibodies. We also reported a patient with AIH who was diagnosed limited SSc with contemporary presence of anti-centromere A and anti-RNA polymerase III antibody. Conclusion: We suggest that SSc may be considered to be one of the manifestations associated with AIH. Patients with AIH may have an increased risk to develop SSc and should be followed, especially when Raynaud phenomenon was found.",
keywords = "Autoimmune hepatitis, Autoimmune liver diseases, Systemic sclerosis",
author = "Roberto Assandri and Marta Monari and Alessandro Montanelli",
year = "2016",
language = "English",
volume = "9",
pages = "211--219",
journal = "Gastroenterology and Hepatology from Bed to Bench",
issn = "2008-2258",
publisher = "Shahid Beheshti Medical University",
number = "3",

}

TY - JOUR

T1 - Development of systemic sclerosis in patients with autoimmune hepatitis

T2 - An emerging overlap syndrome

AU - Assandri, Roberto

AU - Monari, Marta

AU - Montanelli, Alessandro

PY - 2016

Y1 - 2016

N2 - Aim: We described two case reports of AIH/SSc overlap syndrome and reviewed literatures regarding this issue. Background: AIH is a chronic hepatitis of unknown aetiology characterized by continuing hepatocellular necrosis and inflammation. AIH overlap syndromes have been reported with other autoimmune diseases. Patients and methods: According to the classification criteria for SSc, we conducted a retrospective chart review of 35 cases with biopsy-proven AIH over the past 5 years at our institution. We reviewed the MEDLINE database using the appropriate key-words. Results: A chart review of 35 cases (M/F ratio 1:2, mean age 47.6±10.3 years) revealed nine patients (9/35, 25.7%) with CTD (four males and three females with a mean age of 45.1±8.4 years). All patients had ANA. Four patients were SSA/Ro positive UCTD (1/35, 2.85%), and six patients developed SLE (6/35, 17.1%). Only two female patients (2/35, 5.7%) with specific SSc AAb developed a systemic sclerosis. We described a patient with AIH who was diagnosed with diffuse systemic sclerosis-sine scleroderma with positive anti-centromere B and SSA/Ro52 KDa antibodies. We also reported a patient with AIH who was diagnosed limited SSc with contemporary presence of anti-centromere A and anti-RNA polymerase III antibody. Conclusion: We suggest that SSc may be considered to be one of the manifestations associated with AIH. Patients with AIH may have an increased risk to develop SSc and should be followed, especially when Raynaud phenomenon was found.

AB - Aim: We described two case reports of AIH/SSc overlap syndrome and reviewed literatures regarding this issue. Background: AIH is a chronic hepatitis of unknown aetiology characterized by continuing hepatocellular necrosis and inflammation. AIH overlap syndromes have been reported with other autoimmune diseases. Patients and methods: According to the classification criteria for SSc, we conducted a retrospective chart review of 35 cases with biopsy-proven AIH over the past 5 years at our institution. We reviewed the MEDLINE database using the appropriate key-words. Results: A chart review of 35 cases (M/F ratio 1:2, mean age 47.6±10.3 years) revealed nine patients (9/35, 25.7%) with CTD (four males and three females with a mean age of 45.1±8.4 years). All patients had ANA. Four patients were SSA/Ro positive UCTD (1/35, 2.85%), and six patients developed SLE (6/35, 17.1%). Only two female patients (2/35, 5.7%) with specific SSc AAb developed a systemic sclerosis. We described a patient with AIH who was diagnosed with diffuse systemic sclerosis-sine scleroderma with positive anti-centromere B and SSA/Ro52 KDa antibodies. We also reported a patient with AIH who was diagnosed limited SSc with contemporary presence of anti-centromere A and anti-RNA polymerase III antibody. Conclusion: We suggest that SSc may be considered to be one of the manifestations associated with AIH. Patients with AIH may have an increased risk to develop SSc and should be followed, especially when Raynaud phenomenon was found.

KW - Autoimmune hepatitis

KW - Autoimmune liver diseases

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84976260659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976260659&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 211

EP - 219

JO - Gastroenterology and Hepatology from Bed to Bench

JF - Gastroenterology and Hepatology from Bed to Bench

SN - 2008-2258

IS - 3

ER -